

IN THE CLAIMS

Please amend claims 21 and 32 as follows, without prejudice or disclaimer of the subject matter therein:

21. The kit of claim 20, wherein the pharmaceutical carrier comprises
D1 the nucleic acid.

32. The kit of claim 31, wherein the second gene encodes HLA-B7, an
D2 immunotherapeutic agent, cytokine, or prodrug converting enzyme.

REMARKS

Applicants thank the Examiner for his useful suggestions at the telephonic interview of September 5th, 2002. At the interview, the Examiner informed applicants that claim 1 was inadvertently admitted from the restriction requirement. Applicants reaffirmed their election of claims 17 – 36.

Claims 17 – 36 are pending.

Claims 1 and 37 – 54 are withdrawn from consideration.

PRIORITY

Applicants' claim of priority of U. S. Serial Nos. 08/533,942, 09/031572 and 09/426,325 stands denied. The Examiner alleges that the application adds and claims additional disclosure not presented in the prior applications.